Isturisa (osilodrostat) is now available in Canada for adults with Cushing’s disease who have persistent or recurrent high cortisol after pituitary surgery and/or pituitary irradiation, or who can’t have pituitary surgery, according to Recordati Rare Diseases Canada. The oral medication is approved in the U.S. and the European…
News
The corticotropin-releasing hormone (CRH) stimulation test is a reliable tool for diagnosing Cushing’s disease, according to a recent study. Results show that its accuracy is comparable to that of bilateral inferior petrosal sinus sampling (BIPSS), the gold standard but invasive method, in distinguishing Cushing’s disease from ectopic Cushing’s syndrome.
A woman with type 1 diabetes was diagnosed with Cushing’s disease after her daily insulin needs rose sharply and no longer controlled her blood sugar levels, a case study reports. “This case underscores the importance of regular review of automated insulin delivery data and consideration of [hormonal] causes of…
A diagnostic test using an artificial form of the naturally occurring hormone desmopressin could be a good alternative to the standard test used to diagnose Cushing’s disease in children and adolescents, according to a study. Researchers found that the accuracy of the desmopressin stimulation test (DDAVP) was comparable to…
Although acinic cell carcinoma — a cancer of the glands that produce saliva — is usually considered low risk, it can behave aggressively and cause Cushing’s syndrome, according to researchers who described such a case involving a 58-year-old man in Turkey. They added that if not recognized and treated…
The U.S. Food and Drug Administration (FDA) has declined to approve relacorilant, an experimental oral therapy for patients with Cushing’s syndrome experiencing high blood pressure. In a complete response letter, the agency stated that current data do not yet conclusively show that the treatment’s benefits outweigh its risks. The…
Treatment with Isturisa (osilodrostat) normalized cortisol levels in most people with ectopic Cushing’s syndrome, including those with severe disease, according to real-world data from Spain. Normal cortisol levels were reached within a month of starting treatment in more than a third of patients (36%). “Therefore, [Isturisa] should be considered…
Asymptomatic Cushing’s syndrome alongside primary hyperaldosteronism, or PHA — a disorder marked by excessive secretion of the hormone aldosterone — was found to be the cause of persistent, hard-to-treat high blood pressure in a 57-year-old man, according to a new case study. The research team, from Iran, noted the “diagnostic…
A woman with persistent Cushing’s disease experienced two back-to-back pregnancies without significant problems for the mother or baby, a case study reported. “There are a limited number of cases of Cushing’s [disease] in pregnancy, therefore the best possible treatment is difficult to determine and should be individualised to the…
Isturisa (osilodrostat) can safely reduce, or even normalize, cortisol levels in people with various forms of endogenous Cushing’s syndrome that are not Cushing’s disease, according to data from a real-world study in France. The study, “Real-world osilodrostat effectiveness and safety in non-pituitary Cushing syndrome,” was…
Recent Posts
- New Cushing’s disease treatment option reaches Canada with Isturisa
- I’m trying to be more honest about how medical trauma affects me
- CRH test may replace invasive method in diagnosing Cushing’s disease: Study
- Unexpected insulin resistance exposes rare Cushing’s disease diagnosis
- The challenges of managing Cushing’s disease during the postpartum period
- Test may be ‘practical’ alternative for diagnosing Cushing’s in kids
- Man’s aggressive salivary gland cancer triggers Cushing’s syndrome: Report
- FDA rejects relacorilant for Cushing’s-related high blood pressure
- Study supports Isturisa as first-line ectopic Cushing’s treatment
- After some scary complications, I finally gave birth to a baby girl